Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ord, J J, Streeter, E, Jones, A, Le Monnier, K, Cranston, D, Crew, J, Joel, S P, Rogers, M A, Banks, R E, Roberts, I S D, Harris, A L
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2005
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361814/
https://ncbi.nlm.nih.gov/pubmed/15928663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602650
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars